Greiner Bio-One looks back on a successful financial year 2021

Last edited: - Back to overview

Since the outbreak of the Covid-19 pandemic, the detection of viruses has increasingly become the focus of public health attention.

Kremsmünster, May 2022 – The VACUETTE® Virus Stabilization Tube (VST) has been used millions of times worldwide for the safe transport of sample material for PCR testing in the laboratory. As a global player, Greiner Bio-One stands by its customers.

Rainer Perneker, CEO Greiner Bio-One International

Successful business development in 2021
In 2021, Greiner Bio-One International GmbH generated a turnover of 695 million euros (+ 0.4 %; FY 2020: EUR 693 million) and had 2,540 employees, 28 subsidiaries and numerous distribution partners in over 100 countries. Greiner Bio-One is part of Greiner AG, which is based in Kremsmünster (Austria).

As in 2020, the VACUETTE® Virus Stabilization Tube (VST) was largely responsible for the extremely positive sales development in the previous year. However, the positive business development in 2021 can also be explained by the increased demand for standard products in both business units Preanalytics and BioScience. The products also play an important role in SARS-CoV2 diagnostics and vaccine development. BioScience products include ELISA microplates, cell culture vessels and mass cell culture products.

Challenges managed thanks to committed employees
As an internationally active company, Greiner Bio-One is strongly affected by the strain and partial interruption of supply chains. Severe delays in international container deliveries and a massive increase in freight costs and raw material prices have had an effect on business operations. The fact that this very challenging situation was managed is on the one hand due to forward-looking planning, but above all to the high commitment of the employees. 

Setting the course for the future: greening and digitalization
In the area of greening, sub-projects were successfully completed. For example, the production sites in Austria and Germany were switched to certified green electricity. In total, the energy efficiency projects saved 1,670 MWh of electricity. 

A trend that has been going on for quite some time and that will continue to become increasingly important in the future is the topic of digitalization in the healthcare sector. Greiner Bio-One has developed a system solution that has already been in use for several years and which will be further developed and distributed in a more targeted manner in the future through a new joint venture.

New slogan “making a difference” 
Last year, the company redefined its value proposition to customers in a large-scale project and, under the slogan "making a difference" in the areas of technology, quality and sustainability, would like to present itself more strongly in the future as a global partner that implements customers' requirements with efficiency and expertise. The goal is to build long-term partnerships based on trust.

Detailed information about Greiner AG can be found here:

Detailed information

Greiner AG Annual Report 2021
Sign-up to our newsletter or request more information here
Register now and you will receive our regular Greiner Bio-One News on current topics to stay up-to-date.

We redirected you to your country page. To go back to the previous page, please click the button.

You are not viewing your country page. To switch to your country, please click the button.